Technology
Health
Pharmaceutical

Aeglea BioTherapeutics

$7.87
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.03 (-0.38%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell AGLE and other stocks, options, ETFs, and crypto commission-free!

About

Aeglea Biotherapeutics, Inc. operates as a clinical-stage biotechnology company, which engages in the design and development of human enzyme therapeutics for patients with rare genetic diseases and cancer. It develops pegzilarginase, its lead investigational therapy for the treatment of Arginase 1 Deficiency, as monotherapy in arginine-dependent cancers and in combination with an immune checkpoint inhibitor for small cell lung cancer. Read More The company was founded by George Georgiou and David G. Lowe in December 2013 and is headquartered in Austin, TX.

Employees
61
Headquarters
Austin, Texas
Founded
2013
Market Cap
190.71M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
201.91K
High Today
$8.01
Low Today
$7.83
Open Price
$7.90
Volume
46.66K
52 Week High
$12.00
52 Week Low
$6.31

Collections

Technology
Health
Pharmaceutical
Therapy
Medical
Cancer Prevention
Biotechnology
2016 IPO

News

MarketWatchMar 21

Aeglea BioTherapeutics Inc.

Aeglea BioTherapeutics Inc. Aeglea Biotherapeutics, Inc. operates as a clinical-stage biotechnology company, which engages in the design and development of human enzyme therapeutics for patients with rare genetic diseases and cancer. It develops pegzilarginase, its lead investigational therapy for the treatment of Arginase 1 Deficiency, as monotherapy in arginine-dependent cancers and in combination with an immune checkpoint inhibitor for small cell lung cancer. The company was founded by George Georgiou a...

34
The Motley FoolMar 8

Aeglea BioTherapeutics (AGLE) Q4 2018 Earnings Conference Call Transcript

Aeglea BioTherapeutics (NASDAQ:AGLE) Q4 2018 Earnings Conference Call March 7, 2019 4:30 p.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Greetings, and welcome to the fourth quarter 2018 corporate update and earnings call. [Operator instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Mr. David Calusdian. Thank you, Mr. Calusdian. You may begin. David Calusdian -- Investor R...

32
Seeking AlphaMar 7

Aeglea BioTherapeutics' (AGLE) CEO Anthony Quinn on Q4 2018 Results - Earnings Call Transcript

Aeglea BioTherapeutics (NASDAQ:AGLE) Q4 2018 Earnings Conference Call March 7, 2019 4:30 PM ET Company Participants David Calusdian - IR, Sharon Merrill Associates Anthony Quinn - Chief Executive Officer Charles York - Chief Financial Officer Jim Wooldridge - Chief Medical Officer Conference Call Participants Josh Schimmer - Evercore ISI Rajvindra Gill - Needham and Company Matthew Cross - H.C. Wainwright Operator Greetings and welcome to the Fourth Quarter 2018 Corporate Update and Earnings Call...

5

Earnings

-$0.64
-$0.55
-$0.46
-$0.37
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 7, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.